Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

50%

4 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

4(66.7%)

Phase 2

1(16.7%)

N/A

1(16.7%)

6Total

Phase 3(4)

Phase 2(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT03803228Phase 3Completed

Dual Ovarian Stimulation (DUOSTIM) for Poor Ovarian Responders

Role: collaborator

NCT02703740Not ApplicableCompleted

Long Term Safety and Efficacy Assessment of Hyaluronic Acid Dermal Filler With for the Treatment of Nasolabial Folds

Role: lead

NCT02156427Phase 3Completed

Evaluation of Non-cultured Epidermal Cellular Grafting vs Hyaluronic Acid for Repigmenting Vitiligo and Piebaldism

Role: lead

NCT04124133Completed

Evaluation of Efficacy and Safety of Ialuset Cream and Gauze in Second-degree Burns on Child

Role: lead

NCT04114240Completed

French Study in Real Life Evaluating Xybilun

Role: lead

NCT00521937Phase 3Unknown

Efficacy and Safety Study of DERMAGEN® vs Conventional Treatment to Treat Diabetic Neuropathic Foot Ulcer

Role: lead

NCT01058603Phase 3Unknown

Efficacy of Endocell® vs Conventional Medium in the Treatment of Infertility

Role: lead

NCT00366041Phase 2Terminated

Efficacy and Tolerance of Cellularised LG002 Versus Uncellularised LG002 in the Treatment of Severe Burns Injuries

Role: lead

All 8 trials loaded